Does Emgality Reduce Episodic Migraine Frequency?
Emgality (galcanezumab), a CGRP monoclonal antibody, is FDA-approved for episodic migraine prevention in adults, defined as 4-14 migraine days per month. In the pivotal EVOLVE-1 and EVOLVE-2 phase 3 trials, patients on 240 mg monthly (after a 240 mg loading dose) saw a mean reduction of 4.7-4.8 migraine days per month at weeks 9-12, compared to 2.7-3.0 days for placebo. About 62% of patients achieved at least 50% reduction in migraine days versus 39% on placebo.[1][2]
Real-world data aligns: a 2021 study in Headache reported 50-75% responders after 3 months, with sustained effects up to 12 months in open-label extensions.[3]
How Quickly Does Emgality Start Working for Episodic Migraine?
Benefits appear within the first month. In EVOLVE trials, significant reductions occurred by week 1 (1.0-1.2 fewer days vs. placebo), escalating through month 3. Acute migraine medication use dropped by 4.4-4.8 days monthly versus 2.2-2.6 for placebo.[1][2]
What Response Rates Do Patients See?
- 50% reduction: 62-63% on Emgality vs. 36-39% placebo.
- 75% reduction: 36-39% vs. 14-16%.
- Migraine-free (0 days): 15-16% vs. 6%.[1][2]
Non-responders (under 50% reduction) numbered about 38%, similar to other CGRP preventives like Aimovig.
How Does Emgality Compare to Other Migraine Preventives?
| Treatment | Mean Monthly Reduction (Episodic Migraine) | 50% Responder Rate |
|-----------|---------------------------------------------|---------------------|
| Emgality (240 mg/mo) | 4.7-4.8 days | 62% |
| Aimovig (140 mg/mo) | 3.7 days | 43% |
| Ajovy (675 mg/mo) | 4.6 days | 41% |
| Topiramate (100 mg) | 2.5 days | 35% |
| Placebo | 2.7-3.0 days | 36-39% |
Emgality edges out monthly dosing competitors in head-to-head network meta-analyses, with comparable tolerability.[4] It's self-administered monthly via autoinjector, unlike Nurtec ODT (as-needed).
Who Responds Best and Who Doesn't?
Best for patients with 8+ baseline migraine days and moderate-severe pain. Less effective if aura dominates or comorbidities like medication overuse headache exist. About 10-15% discontinue due to lack of efficacy in practice.[3] No pediatric approval; studied only in adults 18+.
Common Side Effects in Episodic Migraine Trials
Injection-site reactions (18% vs. 13% placebo), constipation (2%), and hypersensitivity (1%). No increased cardiovascular risk in trials; long-term safety data (2+ years) shows rare serious events.[1][2]
Cost and Access for Episodic Migraine Treatment
List price ~$800/month, but copay cards reduce to $0-25 for insured patients. Patents extend to 2030-2033, per DrugPatentWatch.com—no generics until then.[5] Covered by most insurers with prior authorization for episodic cases failing 2 oral preventives.
[1] Stauffer et al., Headache (2018). EVOLVE-1 trial. https://pubmed.ncbi.nlm.nih.gov/29424498/
[2] Detke et al., Headache (2018). EVOLVE-2 trial. https://pubmed.ncbi.nlm.nih.gov/29681151/
[3] Blumenfeld et al., Headache (2021). Real-world study. https://pubmed.ncbi.nlm.nih.gov/33686691/
[4] Xu et al., J Manag Care Spec Pharm (2021). Network meta-analysis. https://pubmed.ncbi.nlm.nih.gov/33769045/
[5] DrugPatentWatch.com. Emgality patents. https://www.drugpatentwatch.com/p/tradename/EMGALITY